Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) — Cash Flow Quality Index
Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) has a Cash Flow Quality Index of 3.51x as of September 2025. Operating cash flow of CN¥502.01 Million exceeds net income of CN¥143.20 Million, indicating high earnings quality where cash backs reported profits. Explore cash flow to debt ratio of Nanjing King-friend Biochemical Pharmace to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Nanjing King-friend Biochemical Pharmaceutical Co Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 603707 cash generation efficiency.
Annual Cash Flow Quality Index for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2025)
Year-by-year earnings quality comparison for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.03x | CN¥1.18 Billion | CN¥581.54 Million | ▲ +11.9% |
| 2024 | 1.82x | CN¥1.50 Billion | CN¥826.10 Million | ▲ +231.6% |
| 2022 | 0.55x | CN¥595.45 Million | CN¥1.09 Billion | ▼ -14.7% |
| 2021 | 0.64x | CN¥683.63 Million | CN¥1.06 Billion | ▲ +190.5% |
| 2020 | -0.71x | CN¥-565.85 Million | CN¥796.65 Million | ▲ +48.8% |
| 2019 | -1.39x | CN¥-841.38 Million | CN¥606.24 Million | ▼ -1044.7% |
| 2018 | 0.15x | CN¥62.37 Million | CN¥424.55 Million | ▲ +119.7% |
| 2017 | -0.75x | CN¥-234.59 Million | CN¥314.22 Million | ▲ +33.0% |
| 2016 | -1.11x | CN¥-286.79 Million | CN¥257.24 Million | ▼ -171.1% |
| 2015 | 1.57x | CN¥137.28 Million | CN¥87.55 Million | ▼ -55.7% |
| 2014 | 3.54x | CN¥178.74 Million | CN¥50.46 Million | ▲ +28.4% |
| 2013 | 2.76x | CN¥193.91 Million | CN¥70.31 Million | — |